Results 291 to 300 of about 90,274 (350)
Tumor evolution in lung adenocarcinoma is shaped by genetic alterations and spatial immune dynamics. By integrating whole‐exome sequencing, imaging mass cytometry, and spatial transcriptomics across two mouse models, this study reveals how mutational burden, immune infiltration, and cell–state interactions evolve during early and late carcinogenesis ...
Bo Zhu +34 more
wiley +1 more source
Correction: Tumor organoids may be more suitable for clinical personalized chemotherapeutic drug screening in lung adenocarcinoma. [PDF]
Yun W +6 more
europepmc +1 more source
PBRM1 ranks as the second most commonly mutated gene in ccRCC. This study reveals that PBRM1 loss promotes an immunosuppressive microenvironment by elevating M2 TAMs via the KDM5C–IL‐6 axis. These M2 TAMs, along with CAFs, form a barrier that excludes CD8+ T cells. Targeting IL‐6 synergizes with anti‐PD1 therapy, offering a promising strategy for PBRM1‐
Wenjiao Xia +14 more
wiley +1 more source
Lightweight Deep Learning Model for Classification of Normal and Abnormal Vasculature in Organoid Images. [PDF]
Yun E, Kim J, Jeong D.
europepmc +1 more source
Single‐cell sequencing reveals stress‐programmed immune states driving TNFα–TNFR2–mediated Treg activation and therapy resistance in breast cancer, while targeting this axis restores antitumor immunity. ABSTRACT The tumor microenvironment (TME) harbors diverse immune cell states that shape therapeutic outcomes in breast cancer.
Zhibo Shao +18 more
wiley +1 more source
Establishment of Mouse Meibomian Gland Organoids for In Vitro Modeling of Meibomian Gland Dysfunction. [PDF]
Qu J +11 more
europepmc +1 more source
ImageJ macros for quantitative analysis of cell death in human intestinal organoids
Pang, Jiyi, Whitehead, Lachlan
openalex +1 more source
Multiomic profiling of HER2‐low breast cancer identifies three proteomic subtypes with distinct therapeutic strategies: endocrine, antiangiogenic, and anti‐HER2 therapies. Genomic and lactate modification landscapes are detailed, providing insights for precise management.
Shouping Xu +20 more
wiley +1 more source
From Cells to Organoids: Approaches, Regulatory Mechanisms, Applications, and Challenges of Organoids. [PDF]
Wang L, Chen A, Zhang D, He Z.
europepmc +1 more source
Dual Targeting of Tau Kinases and Autophagy by Abemaciclib Independent of CDK4/6 Inhibition
Abemaciclib rescues cognitive function and attenuates tau pathology in Alzheimer's disease models, but not through its known cancer‐fighting mechanism. This study demonstrates that abemaciclib operates independently of CDK4/6 inhibition, instead directly targeting tau kinases CaMKII and GSK3β while simultaneously promoting autophagic clearance of ...
Jihui Han +9 more
wiley +1 more source

